Key takeaways

  • BPC-157 is a lab-made peptide that is not approved for any medical use.
  • Most studies are in rats, and most come from one research group.
  • There are almost no human trials, so its safety and effects in people are unknown.

BPC stands for “body protection compound.” BPC-157 is a short chain of 15 amino acids based on part of a protein found in human stomach juice. The version people talk about is made in a lab.

Where does the interest come from?

Over the past three decades, researchers have published dozens of studies in rats suggesting BPC-157 can speed the healing of tendons, ligaments, muscle and the lining of the gut. Those results spread through fitness and wellness communities online.

There are two big caveats. Most of these studies come from a single research group in Croatia, and few have been repeated independently. And results in rats often do not hold up in people.

Has it been tested in humans?

Barely. The published human data consist of a few small reports without control groups. No large randomized trial has been completed. That means nobody knows whether BPC-157 works in people, or what it does to the body over time.

BPC-157 is not approved by the FDA for any use. In 2023 the FDA restricted pharmacies from compounding it, citing a lack of safety data and the risk of immune reactions. In April 2026 it was taken off that restricted list after the original nominations were withdrawn. That change was not a finding that it is safe or effective, and it does not make BPC-157 an approved drug.

The World Anti-Doping Agency bans it in sport.

What are the risks?

  • No established safety profile in humans.
  • Products sold outside regulated pharmacies may be mislabeled or contaminated.
  • Researchers have raised a theoretical concern that a substance that promotes blood vessel growth could also feed unwanted tissue growth. This has not been studied.

The bottom line

BPC-157 has an interesting animal research record and almost no human evidence. Claims about what it does in people go well beyond what has been studied.

References

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377:153-159.
  2. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (2023) and status update (April 2026).
  3. World Anti-Doping Agency. The Prohibited List.